Neurotherapeutics

, Volume 14, Issue 1, pp 54–61

Amyloid Imaging: Poised for Integration into Medical Practice

Review

DOI: 10.1007/s13311-016-0474-y

Cite this article as:
Anand, K. & Sabbagh, M. Neurotherapeutics (2017) 14: 54. doi:10.1007/s13311-016-0474-y

Abstract

Amyloid imaging represents a significant advance as an adjunct in the diagnosis of Alzheimer’s disease (AD) because it is the first imaging modality that identifies in vivo changes known to be associated with the pathogenesis. Initially, 11C-PIB was developed, which was the prototype for many 18F compounds, including florbetapir, florbetaben, and flutemetamol, among others. Despite the high sensitivity and specificity of amyloid imaging, it is not commonly used in clinical practice, mainly because it is not reimbursed under current Center for Medicare and Medicaid Services guidelines in the USA. To guide the field in who would be most appropriate for the utility of amyloid positron emission tomography, current studies are underway [Imaging Dementia Evidence for Amyloid Scanning (IDEAS) Study] that will inform the field on the utilization of amyloid positron emission tomography in clinical practice. With the advent of monoclonal antibodies that specifically target amyloid antibody, there is an interest, possibly a mandate, to screen potential treatment recipients to ensure that they are suitable for treatment. In this review, we summarize progress in the field to date.

Key Words

Alzheimer’s disease amyloid imaging therapeutics PET-CT 

Supplementary material

13311_2016_474_MOESM1_ESM.pdf (518 kb)
ESM 1(PDF 517 kb)

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2016

Authors and Affiliations

  1. 1.St. Joseph’s Hospital and Medical CenterPhoenixUSA
  2. 2.Alzhiemer’s and Memory Disorders Division, Barrow Neurological InstitutePhoenixUSA

Personalised recommendations